Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116857 · ClinicalTrials.gov registry record · Phase 3
Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors
A Phase 3 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT00116857 is a Phase 3 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 122 participants.
The verdict
NCT00116857, a Phase 3 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
This study will determine the effects of omega-3 fatty acid (FA) augmentation of sertraline on depression and cardiac endpoints after myocardial infarction (MI).
Interventions
- DRUG Sertraline/omega-3
- DRUG Sertraline/Corn Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2005-02 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116857
The ClinicalTrials.gov registry entry for NCT00116857 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sertraline/omega-3 is the first listed.
NCT00116857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116857 about?
NCT00116857 is a clinical study titled "Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors". This study will determine the effects of omega-3 fatty acid (FA) augmentation of sertraline on depression and cardiac endpoints after myocardial infarction (MI).
What is the current status of trial NCT00116857?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2005-02. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00116857?
The interventions under investigation include: Sertraline/omega-3 (DRUG), Sertraline/Corn Oil (DRUG).
Who is sponsoring clinical trial NCT00116857?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.